Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

@article{Bukowski2002TreatingCW,
  title={Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.},
  author={Ronald M. Bukowski and Craig L. Tendler and David Cutler and Esther Rose and Mark M Laughlin and Paul Statkevich},
  journal={Cancer},
  year={2002},
  volume={95 2},
  pages={389-96}
}
BACKGROUND PEG Intron (pegylated interferon-alpha-2b [IFN-alpha-2b]; Schering-Plough, Kenilworth, NJ) has demonstrated delayed clearance and increased area under the curve compared with native IFN-alpha-2b. Studies in patients with chronic hepatitis C infection and malignancies have demonstrated both biologic and clinical activity of PEG Intron and have provided empiric data to compare the pharmacokinetics (PK) and pharmacodynamics of PEG Intron and IFN-alpha-2b. METHODS The authors conducted… CONTINUE READING